Early postpartum pharmacokinetics of Lopinavir initiated intrapartum in thai women Cressey, T. Van Dyke, R. /Jourdain, Gonzague Puthanakit, T. Roongpisuthipong, A. Achalapong, J. Yuthavisuthi, P. Prommas, S. Chotivanich, N. Maupin, R. Smith, E. Shapiro, D. E. Mirochnick, M. Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) mu g.h/ml, 11.2 (8.0 to 17.5) mu g/ml, and 4.6 (1.7 to 12.5) mu g/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported. 2009 text https://www.documentation.ird.fr/hor/PAR00003512 PAR00003512 Cressey T., Van Dyke R., Jourdain Gonzague, Puthanakit T., Roongpisuthipong A., Achalapong J., Yuthavisuthi P., Prommas S., Chotivanich N., Maupin R., Smith E., Shapiro D. E., Mirochnick M.. Early postpartum pharmacokinetics of Lopinavir initiated intrapartum in thai women. 2009, 53 (5), 2189-2191 EN THAILANDE